Log in
NASDAQ:RVNC

Revance Therapeutics Stock Forecast, Price & News

$31.95
-0.16 (-0.50 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$31.14
Now: $31.95
$33.29
50-Day Range
$23.48
MA: $26.70
$34.30
52-Week Range
$11.62
Now: $31.95
$34.62
Volume2.00 million shs
Average Volume713,969 shs
Market Capitalization$2.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.73
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Read More
Revance Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$410,000.00
Book Value$5.00 per share

Profitability

Net Income$-159,430,000.00
Net Margins-42,532.11%

Miscellaneous

Employees170
Market Cap$2.11 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$31.95
-0.16 (-0.50 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

How has Revance Therapeutics' stock been impacted by COVID-19?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RVNC stock has increased by 77.8% and is now trading at $31.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Revance Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Revance Therapeutics
.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Revance Therapeutics
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.96) by $0.16. The biopharmaceutical company earned $0.30 million during the quarter, compared to analyst estimates of $1.05 million. Revance Therapeutics had a negative net margin of 42,532.11% and a negative return on equity of 88.96%.
View Revance Therapeutics' earnings history
.

What price target have analysts set for RVNC?

8 brokerages have issued 12 month target prices for Revance Therapeutics' stock. Their forecasts range from $15.00 to $40.00. On average, they anticipate Revance Therapeutics' share price to reach $28.71 in the next twelve months. This suggests that the stock has a possible downside of 10.1%.
View analysts' price targets for Revance Therapeutics
.

Who are some of Revance Therapeutics' key competitors?

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), Myovant Sciences (MYOV), AbbVie (ABBV), SCYNEXIS (SCYX), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Immunomedics (IMMU).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:
  • Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 56)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (5.43%), Vanguard Group Inc. (4.39%), Jennison Associates LLC (3.73%), Driehaus Capital Management LLC (1.14%), Bamco Inc. NY (0.88%) and Principal Financial Group Inc. (0.99%). Company insiders that own Revance Therapeutics stock include Cyril Allouche and L Daniel Browne.
View institutional ownership trends for Revance Therapeutics
.

Which institutional investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, State of Wisconsin Investment Board, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., EAM Investors LLC, Essex Investment Management Co. LLC, and Glenmede Trust Co. NA.
View insider buying and selling activity for Revance Therapeutics
.

Which institutional investors are buying Revance Therapeutics stock?

RVNC stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Vanguard Group Inc., Principal Financial Group Inc., Principal Financial Group Inc., HAP Trading LLC, Bamco Inc. NY, Bessemer Group Inc., and First Trust Advisors LP.
View insider buying and selling activity for Revance Therapeutics
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $31.95.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $2.11 billion and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.